Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Completed 28Active not recruiting 9Terminated 3Withdrawn 1Approved for marketing 1

Sponsor Class

OTHER 7NIH 4INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Differentiated Thyroid Cancer 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × AZD 6244 × Clear all
NCT03833427 2024-11-07

MK-5618-001

Merck Sharp & Dohme LLC

Phase 1 Terminated
32 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT01843062 2019-08-28

ASTRA

AstraZeneca

Phase 3 Terminated
233 enrolled 14 charts
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT01949870 2016-05-13

Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study

AstraZeneca

Phase 1 Terminated
6 enrolled 6 charts
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡